» Articles » PMID: 6812716

A Case of Lassa Fever: Clinical and Virological Findings

Overview
Specialty General Medicine
Date 1982 Oct 9
PMID 6812716
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Five days after arriving in London from Jos a young Nigerian women developed a severe and prolonged illness that proved to be Lassa fever. Virus was not detected in urine during the first three weeks but then appeared and reached a peak during the sixth week, with continuing excretion for 67 days after the onset of illness. Laboratory investigations showed evidence of extensive tissue damage and disturbance of clotting, but there was no serious bleeding and she eventually made a complete recovery despite a high sustained viraemia and severe liver damage. Convalescent serum was used in treatment but it was difficult to assess its contribution to the favourable outcome.

Citing Articles

Cases of high-consequence infectious diseases identified in the UK, 1962-2023.

Atkinson B, Beadsworth M, Dunning J J Med Microbiol. 2025; 74(3).

PMID: 40071494 PMC: 11903645. DOI: 10.1099/jmm.0.001982.


Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus.

Cross R, Fenton K, Woolsey C, Prasad A, Borisevich V, Agans K Cell Rep Med. 2024; 5(2):101392.

PMID: 38280377 PMC: 10897540. DOI: 10.1016/j.xcrm.2024.101392.


A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus.

Cross R, Heinrich M, Fenton K, Borisevich V, Agans K, Prasad A Proc Natl Acad Sci U S A. 2023; 120(34):e2304876120.

PMID: 37590417 PMC: 10450431. DOI: 10.1073/pnas.2304876120.


Viral RNA and infectious virus in mucosal specimens from guinea pigs modelling early phases of lethal and non-lethal Lassa fever.

Welch S, Genzer S, Coleman-McCray J, Harmon J, Scholte F, Montgomery J Emerg Microbes Infect. 2022; 11(1):1390-1393.

PMID: 35481464 PMC: 9132395. DOI: 10.1080/22221751.2022.2071637.


Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design.

Merson L, Bourner J, Jalloh S, Erber A, Salam A, Flahault A PLoS Negl Trop Dis. 2021; 15(9):e0009788.

PMID: 34547033 PMC: 8486098. DOI: 10.1371/journal.pntd.0009788.


References
1.
LEIFER E, Gocke D, Bourne H . Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease. Am J Trop Med Hyg. 1970; 19(4):677-9. DOI: 10.4269/ajtmh.1970.19.677. View

2.
Keane E, GILLES H . Lassa fever in Panguma Hospital, Sierra Leone, 1973-6. Br Med J. 1977; 1(6073):1399-402. PMC: 1606930. DOI: 10.1136/bmj.1.6073.1399. View

3.
TREXLER P, EMOND R, Evans B . Negative-pressure plastic isolator for patients with dangerous infections. Br Med J. 1977; 2(6086):559-61. PMC: 1631473. DOI: 10.1136/bmj.2.6086.559. View

4.
Clayton A . Lassa immune serum. Bull World Health Organ. 1977; 55(4):435-9. PMC: 2366682. View

5.
Galbraith N, BERRIE J, Forbes P, Young S . Public health aspects of viral haemorrhagic fevers in Britain. R Soc Health J. 1978; 98(4):152-60. DOI: 10.1177/146642407809800407. View